NASDAQ:IMMX - Nasdaq - US45258H1068 - Common Stock - Currency: USD
NASDAQ:IMMX (5/2/2025, 8:02:14 PM)
2.095
+0.06 (+2.7%)
The current stock price of IMMX is 2.095 USD. In the past month the price increased by 32.59%. In the past year, price decreased by -10.85%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.33 | 351.09B | ||
AMGN | AMGEN INC | 13.55 | 151.20B | ||
GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
NTRA | NATERA INC | N/A | 21.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
BIIB | BIOGEN INC | 7.81 | 18.10B |
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 18 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
IMMIX BIOPHARMA INC
11400 West Olympic Blvd., Suite 200
Los Angeles CALIFORNIA US
Employees: 16
Phone: 18889581084
The current stock price of IMMX is 2.095 USD. The price increased by 2.7% in the last trading session.
The exchange symbol of IMMIX BIOPHARMA INC is IMMX and it is listed on the Nasdaq exchange.
IMMX stock is listed on the Nasdaq exchange.
7 analysts have analysed IMMX and the average price target is 7.14 USD. This implies a price increase of 240.81% is expected in the next year compared to the current price of 2.095. Check the IMMIX BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IMMIX BIOPHARMA INC (IMMX) has a market capitalization of 58.07M USD. This makes IMMX a Micro Cap stock.
IMMIX BIOPHARMA INC (IMMX) currently has 16 employees.
IMMIX BIOPHARMA INC (IMMX) has a support level at 1.34 and a resistance level at 2.1. Check the full technical report for a detailed analysis of IMMX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IMMX does not pay a dividend.
IMMIX BIOPHARMA INC (IMMX) will report earnings on 2025-05-07.
IMMIX BIOPHARMA INC (IMMX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
The outstanding short interest for IMMIX BIOPHARMA INC (IMMX) is 1.15% of its float. Check the ownership tab for more information on the IMMX short interest.
ChartMill assigns a technical rating of 6 / 10 to IMMX. When comparing the yearly performance of all stocks, IMMX turns out to be only a medium performer in the overall market: it outperformed 49.72% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to IMMX. The financial health of IMMX is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months IMMX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS increased by 11.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -94.18% | ||
ROE | -163.11% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to IMMX. The Buy consensus is the average rating of analysts ratings from 7 analysts.